Alkermes plc (NASDAQ:ALKS) management will conduct a conference call for 29th October 2020 at 8:00 AM Eastern Time to discuss financial results and companys performance for 3Q20.
The conference call will also be available live on the website www.alkermes.com
Earnings Expectation
Alkermes plc is expected to report third quarter earnings results, before market open, on Thursday 29th October 2020. Analysts polled by Thomson Reuters anticipate third quarter revenue of $ 238.39 million. Looking ahead, the full year income are expected at $ 0.10 per share on the revenues of $ 982.45 million.
The Company Outlook
Full Year 2020 topline are forecasted in a range of$ 965.00 million ~ $ 1,005.00 million, where as bottomline are predicted in a range of $ 0.25 ~ $ 0.43 per share
Click Here For More Historical Outlooks Of Alkermes plc
Alkermes plc, a biopharmaceutical company, researches, develops, and commercializes pharmaceutical products to address unmet medical needs of patients in various therapeutic areas in the United States, Ireland, and internationally. The companys marketed products include ARISTADA (aripiprazole lauroxil), an extended-release intramuscular injectable suspension for the treatment of schizophrenia; VIVITROL (naltrexone for extended-release injectable suspension) for the treatment of alcohol and opioid dependence; RISPERDAL CONSTA for the treatment of schizophrenia and bipolar I disorder; INVEGA SUSTENNA for the treatment of schizophrenia and schizoaffective disorder; XEPLION, INVEGA TRINZA, and TREVICTA for treating schizophrenia; and AMPYRA (dalfampridine)/FAMPYRA (fampridine) to enhance walking in adults with multiple sclerosis (MS) who have walking disability. It is also developing BIIB098, a monomethyl fumarate, which is in Phase III clinical trials to treat relapsing forms of MS; ALKS 3831 to treat schizophrenia; ALKS 4230, an engineered fusion protein that is in Phase I clinical trials for cancer immunotherapy; and ALKS 5461 for the treatment of depressive disorders.
